Dr. Xixi Sun

Cooley advised the underwriters of Aardvark Therapeutics, a phase 3 biotech company developing novel small-molecule therapies for metabolic diseases, in connection with Aardvark’s $94.2 million initial public offering (IPO).

Cooley represented Beijing Tiannuo Jiancheng Pharmaceutical Technology, a joint venture of a subsidiary of InnoCare Pharma (HKEX: 09969; SSE: 688428) and a subsidiary of KeyMed Biosciences (HKEX: 02162), in connection with a joint exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody.

Cooley advised the underwriters of BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases, on its $198 million initial public offering.

Cooley advised Jiangsu Hengrui Pharmaceuticals, one of the largest pharmaceutical companies in China, on its licensing of global rights (excluding Greater China) for the development, production and commercialization of three of its proprietary glucagon-like peptide-1 (GLP-1) drugs to Hercules CM Newco, a newly established Delaware company.

Cooley advised Jiangsu Hengrui Pharmaceuticals, a leading global pharmaceutical company headquartered in China with a focus on research, development, manufacturing and commercialization of innovative and high-quality healthcare products, on its strategic collaboration and exclusive worldwide (excluding mainland China) license agreement with Merck KGaA, Darmstadt, Germany and global license agreement (excluding the Greater China region and Korea) with Elevar Therapeutics.